An Extension Study to Investigate the Safety and Durability of Clinical Activity of Idelalisib in Subjects With Hematologic Malignancies
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 May 2017
At a glance
- Drugs Idelalisib (Primary) ; Antineoplastics; Immunotherapies
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 26 Apr 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
- 26 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
- 07 Jun 2016 Results of post-hoc analysis of this and other trials (n=1073) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.